SLS Gets A Shot In The Arm, BLFS Full Of Life, MNOV Soars On NASH Trial Data

SELLAS Life Sciences gained more than 150% on Monday, following positive interim data from its phase 2b independent investigator-sponsored clinical trial of NeuVax in combination with Roche's Herceptin in HER2 1+/2+ breast cancer patients in the adjuvant setting to prevent recurrences.

from RTT - Biotech https://ift.tt/2GwKPMI
via IFTTT